How should I manage a female patient with elevated parathyroid hormone (~120 pg/mL) and mild hypercalcemia (10.5 mg/dL) who is taking hydrochlorothiazide and has mildly low vitamin D?

Management of Elevated PTH and Mild Hypercalcemia in a Patient on Hydrochlorothiazide

Discontinue the hydrochlorothiazide immediately, as thiazide diuretics decrease calcium excretion and can cause or unmask hypercalcemia with pathologic changes in the parathyroid glands, particularly in patients with underlying primary hyperparathyroidism. 1

Initial Diagnostic Approach

This clinical presentation strongly suggests primary hyperparathyroidism (PHPT) that has been unmasked or exacerbated by thiazide therapy. The combination of elevated PTH (120 pg/mL) with hypercalcemia (10.5 mg/dL) is the hallmark biochemical pattern of PHPT 2. However, the concomitant vitamin D deficiency and thiazide use complicate the picture.

Key Diagnostic Considerations:

• Thiazide-associated hypercalcemia (TAH) is the second most common cause of asymptomatic hypercalcemia after PHPT 3
• Thiazides can unmask normocalcemic or mild PHPT by reducing renal calcium excretion 4
• Vitamin D deficiency can mask the severity of PHPT by keeping calcium levels in the "normal" or only mildly elevated range 5, 6
• The FDA label explicitly warns that thiazides decrease calcium excretion and can cause hypercalcemia and hypophosphatemia with pathologic parathyroid changes 1

Immediate Management Steps

1. Stop Hydrochlorothiazide

Switch to an alternative antihypertensive that does not affect calcium metabolism. The FDA drug label specifically states that thiazides should be discontinued before carrying out tests for parathyroid function 1. This is critical because:

• Thiazides artificially lower urinary calcium excretion
• They can worsen hypercalcemia in PHPT patients
• Stopping the medication will reveal the true severity of the underlying parathyroid disorder

2. Correct Vitamin D Deficiency Cautiously

Replete vitamin D to levels >20 ng/mL (>50 nmol/L), but do so with close monitoring of serum calcium. 7, 8

The evidence supports vitamin D repletion even in PHPT:

• Patients with PHPT who have 25-hydroxyvitamin D levels >60 nmol/L have 51% lower PTH levels compared to those with deficient levels, without exhibiting worse hypercalcemia 8
• Vitamin D deficiency in PHPT patients increases the risk of postoperative hypocalcemia and hungry bone syndrome if surgery is eventually needed 5
• Recent evidence suggests that correcting vitamin D deficiency can be accomplished without worsening hypercalcemia in most mild PHPT cases 5, 9

However, there is a critical caveat: One case report documented severe hypercalcemia (14.4 mg/dL) after vitamin D supplementation in a patient with masked PHPT 6. Therefore:

• Start with modest doses of cholecalciferol (1000-2000 IU daily)
• Check serum calcium weekly during the first month of supplementation
• If calcium rises above 11 mg/dL, hold vitamin D and reassess

3. Reassess After Thiazide Discontinuation

Recheck calcium, PTH, phosphorus, and 24-hour urine calcium 2-4 weeks after stopping hydrochlorothiazide. This will reveal:

• Whether hypercalcemia persists (confirming PHPT)
• The true severity of PTH elevation
• Presence of hypercalciuria (which would support PHPT diagnosis)

Definitive Diagnosis and Long-Term Management

If PHPT is Confirmed:

The 2025 French expert consensus provides clear guidance 2:

• Measure fractional excretion of calcium (FeCa) to rule out familial hypocalciuric hypercalcemia
• Assess for target organ damage (bone density, renal imaging for stones/nephrocalcinosis)
• Consider parathyroid imaging if surgery is being contemplated

Medical Management Options:

If the patient is not a surgical candidate or declines surgery:

Interestingly, thiazides may have a role in managing PHPT patients with significant hypercalciuria who are unfit for surgery 4, 10. A retrospective study of 72 PHPT patients treated with hydrochlorothiazide 12.5-50 mg daily showed:

• Significant reduction in urinary calcium (427 mg/d to 251 mg/d, p<0.001)
• Reduction in PTH levels (115 ng/L to 74 ng/L, p<0.001)
• No significant change in serum calcium (10.7 mg/dL to 10.5 mg/dL, p=0.4) 10

However, this approach requires:

• Confirmation that hypercalciuria is present (>250-300 mg/24h)
• Very close monitoring of serum calcium (initially weekly, then monthly)
• Starting with the lowest dose (12.5 mg daily)
• This is a specialized approach and should only be considered after PHPT diagnosis is firmly established

Common Pitfalls to Avoid

1. Do not continue thiazide while working up hyperparathyroidism - it will confound both diagnosis and assessment of disease severity 1

2. Do not withhold vitamin D replacement out of fear of worsening hypercalcemia - the evidence shows that cautious repletion is safe and beneficial in most cases 8, 5, 9

3. Do not assume the elevated PTH is purely secondary to vitamin D deficiency - with a calcium of 10.5 mg/dL, this is PHPT until proven otherwise 2

4. Do not measure PTH while vitamin D is severely deficient - correct vitamin D first to at least 20 ng/mL, then reassess PTH to determine true parathyroid function 7, 2

Monitoring Algorithm

Week 0: Stop hydrochlorothiazide, start vitamin D supplementation (1000-2000 IU daily)

Week 1-4: Check serum calcium weekly

Week 4: Recheck calcium, PTH, phosphorus, 24-hour urine calcium, vitamin D level

Based on results:

• If calcium normalizes and PTH decreases → likely thiazide-induced hypercalcemia, continue vitamin D repletion
• If calcium remains elevated with elevated/inappropriate PTH → confirmed PHPT, refer to endocrinology for surgical evaluation or medical management